No plans to scale back in Japan as AstraZeneca looks to "good quality" growth
This article was originally published in Scrip
With several major new launches coming through and "a lot going on in our portfolio," AstraZeneca sees Japan as a key market and has no plans to reduce local headcount despite the restructuring elsewhere in the group, says the firm's new country president.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.